SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION
Electronic Theses and Dissertations
Item Files
Item Details
- abstract
- A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit.
- subject
- breast cancer
- nanomaterials
- novel therapeutics
- reactive oxygen species
- silver
- contributor
- Singh, Ravi N (committee chair)
- Kridel, Steven J (committee member)
- Kucera, Gregory L (committee member)
- Metheny-Barlow, Linda J (committee member)
- date
- 2017-06-15T08:35:59Z (accessioned)
- 2018-06-14T08:30:10Z (available)
- 2017 (issued)
- degree
- Cancer Biology (discipline)
- embargo
- 2018-06-14 (terms)
- identifier
- http://hdl.handle.net/10339/82205 (uri)
- language
- en (iso)
- publisher
- Wake Forest University
- title
- SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION
- type
- Dissertation